Skip to main content

The opportunity in training CRO professionals

Are CRO training shops likely to ride on the coattails of the boom in the Clinical Research Outsourcing sector? Businessworld has an article on the mushrooming of such shops.
New Delhi’s Institute of Clinical Research India (ICRI) is a good example. Started in 2004, with about 100 students, it currently trains eight times as many across India, says Dean S.K. Gupta. Five hundred of these are enrolled in a two-year master’s degree programme costing Rs 5,40,000, comparable to what is charged by India’s premier business schools. The rest are pursuing part-time diplomas, costing about Rs 1 lakh. Gupta says the institute turned down hundreds of students across various courses this year. ICRI is in four metros and plans to expand to another two in 2008. Other schools that BW spoke to also report increasing demand. They are also in expansion mode.

Surprisingly, employers are still complaining. There is very little difference between a fresh graduate and one trained from some of these schools, they say. “Not more than 10 per cent are suitable for an entry-level job,” says Arun Bhatt, president of ClinInvent, a Mumbai-based CRO. “Many of them have gone through the text book but when it comes to communication, confidence, and abilities they are just are not there.” Employers whom BW spoke to identified some key problems. One is the absence of practical training. Their biggest complaint is that students, for all their ability to recite from the rulebook, have no ‘on-ground’ experience. Take the example of a clinical trial monitor — the person who is most in touch with the investigator doing a trial, to ensure that it is done the right way. The average age of a monitor today is about 25. But investigators in leading hospitals can be as old as their teachers, even older. “Making the head of a department work to your needs requires a lot of assertiveness,” says Clinpharm’s Tamhankar. And this is put to the acid test only in a real trial, which schools don’t or can’t expose students to.

The absence of applied learning is a problem that has long plagued India’s education system. Employers have surmounted it the only way they know — on-the-job training. But in an industry as complex as this one — where patient safety and company reputations hang in the balance — companies don’t take any chances. “Sponsors (pharma companies whose drugs are being tested) only want monitors with experience,” says Vasudeo Ginde, managing director of Mumbai’s iGate Clinical Research. “It is difficult for me to stick my neck out and say I’ll put the freshers there.”

Click Here for a chart on the players in this field.

Arun Natarajan is the Founder & CEO of Venture Intelligence, the leading provider of information and networking services to the private equity and venture capital ecosystem in India. View free samples of Venture Intelligence newsletters and reports.

Popular posts from this blog

PE-VC investments decline 8% to $6.2 B in Q1'24

Press Release: Private Equity - Venture Capital (PE-VC) firms invested over $6.2 Billion (across 205 deals) in Indian companies during the first three months of 2024, shows data from  Venture Intelligence , a research service focused on private company financials, transactions, and their valuations. (Note: These figures include Venture Capital type investments, but exclude PE investments in Real Estate). The investment amount represents a 8% fall over the $6.7 Billion (across 242 deals) invested in the same period during 2023 and also down by 6% when compared to the immediate previous quarter (which witnessed $6.6 Billion being invested across 200 deals). Deal volumes in Q1'24 also declined 15% compared to Q1'23 and were up by 3% compared to the immediate previous quarter.  Q1’24 witnessed 8 mega deals ($100 M+ rounds) worth $3.5 Billion, compared to 17 such investments (worth $3.6 Billion) in Q1’23 and 15 such deals (worth $4.1 Billion) in the immediate previous quarter.  Th

PE-VC investments in Q2'23 decline 33% to $9.9 Billion

Private Equity-Venture Capital (PE-VC) investments in India during the quarter ended June 2023 (Q2'23), at $9.85 Billion across 182 deals, registered a 33% decrease compared to the same period in 2022 (which saw $14.6 Billion being invested across 371 deals). The investment amount however rose 74% compared to the immediate previous quarter (which saw $5.7 Billion being invested across 181 deals), shows data from  Venture Intelligence , a research service focused on private company financials, transactions, and their valuations. The PE-VC investment figures for the first 6 months of 2023 - at $15.5 Billion (across 363 deals) - was 50% lower compared to the same period in 2022 (which saw $31 Billion being invested across 800 deals). Q2’23 witnessed 19 mega deals ($100 M+

Chiratae, Speciale and Stride Ventures win APEX'24 Venture Capital Awards

Chiratae Ventures, Speciale Invest and Stride Ventures were awarded as among the leading Venture Capital investors in India for 2023 as part of Venture Intelligence APEX‘24 Private Equity & Venture Capital awards event in Mumbai.  The Venture Intelligence “Awards for Private Equity Excellence” (APEX) is dedicated to celebrating the best that the Indian Private Equity & Venture Capital industry has to offer. The APEX Awardees are selected based on both Self Nomination by the participating PE-VC firms and "crowd sourced" voting from the Limited Partner, PE-VC and advisory communities. (The main criteria are Return Track Record, New Fund Raises & Follow-on Funding Rounds for Portfolio Companies) VC Investor of the Year Chiratae Ventures received the Venture Capital Investor of the Year 2023 Award on the back of 10 part exits totaling $178 million via Secondary Sales during the year. Its exits included those from retail unicorn Lenskart, SaaS Startup Pixis and baby pr

Blackstone, MO Alts and InvAscent win APEX'24 Private Equity Awards

Press Release Blackstone, MO Alternates (formerly Motilal Oswal PE) and InvAscent were awarded as among the leading Private Equity and Growth Capital investors in India for 2023 as part of Venture Intelligence APEX‘24 Private Equity & Venture Capital awards event in Mumbai.  The Venture Intelligence “Awards for Private Equity Excellence” (APEX) is dedicated to celebrating the best that the Indian Private Equity & Venture Capital industry has to offer. The APEX Awardees are selected based on both Self Nomination by the participating PE-VC firms and "crowd sourced" voting from the Limited Partner, PE-VC and advisory communities. (The main criteria are Return Track Record, New Fund Raises & Follow-on Funding Rounds for Portfolio Companies) PE Investor of the Year Blackstone received the Private Equity Investor of the Year 2023 Award on the back of strong complete exits during the year: from Sona Comstar and IBS Software. Ganesh Mani and Amit Dalmia, Senior Managing D

Avendus tops League Table for Transaction Advisors to PE deals in Q1'23

Aeka Advisors and Ambit claim the No.2 & 3 slot Avendus topped the Venture Intelligence League Table for Transaction Advisor to Private Equity Transactions for Q1 2023 advising 5 deals worth $808 million. Aeka Advisors stood second having advised 3 deals worth $228 million. Ambit followed with 4 deals worth $160 million. Ernst & Young ($114 million across 4 deals) and o3 Capital ($80 million across 2 deals) completed the top five for Q1 2023. Avendus acted as advisor to ADIA’s $500 million investment in omnichannel eyewear retailer Lenskart . Aeka Advisors acted as advisor to Kreditbee’s $160 million fundraise from Advent International, Mitsubishi UFJ Financial Group (MUFG) and existing investors. Ambit advised the $104 million fundraise of Freshtohome from Mount Judi Ventures, Iron Pillar, Amazon and others. The  Venture Intelligence League Tables , the first such initiative exclusively tracking transactions involving India-based companies, are based on the value of PE